5-甲基胞嘧啶在肝细胞癌患者预后、肿瘤微环境和精准医学适用性中的作用（表4）
基于5-甲基胞嘧啶基因特征的肝细胞癌多队列表格数据，用于预后、免疫微环境和精准医学研究。
基本信息
资源简介
5-甲基胞嘧啶在肝细胞癌患者预后、肿瘤微环境和精准医学适用性中的作用（表4）
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 1 个文件、合计 13.68 KB，主题涵盖 5 mC methylation、hepatocellular carcinoma (HCC)、immune escape、immunotherapy、biomarker，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Table4_Role of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in patients with hepatocellular carcinoma.XLSX》。配套论文《Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level》发表于 European Journal of Cancer（2006），DOI：10.1016/j.ejca.2005.09.034。源站首次发布：2022-09-16。
【数据内容】
源站原始描述：Background: 5-methylcytosine has a profound impact on the development and progression of hepatocellular carcinoma. The aim of this study was to investigate the usefulness of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in hepatocellular carcinoma. Methods: We collected data of seven hepatocellular carcinoma cohorts (The Cancer Genome Atlas, International Cancer Genome Consortium, GSE14520, GSE6764, GSE9843, GSE63898, GSE76427). An…
中文译文（机器翻译，仅供快速理解，请以原文为准）：背景：5-甲基胞嘧啶对肝细胞癌的发生和进展具有深远影响。本研究旨在探讨5-甲基胞嘧啶在判断肝细胞癌预后、肿瘤微环境及精准医学适用性方面的价值。 方法：我们收集了7个肝细胞癌队列的数据（The Cancer Genome Atlas、International Cancer Genome Consortium、GSE14520、GSE6764、GSE9843、GSE63898、GSE76427）。采用无监督聚类方法，基于5-甲基胞嘧啶基因特征表达鉴定肝细胞癌的新亚型。基于所鉴定亚型中基因的差异表达，采用最小绝对收缩和选择算子法确定5-甲基胞嘧啶评分。随后，我们研究了基于5-甲基胞嘧啶的聚类（根据5-甲基胞嘧啶评分）与肝细胞癌临床结局、免疫表型、经典分子亚型及治疗机会之间的关联。最后，我们检测了高5-甲基胞嘧啶评分患者对药物的敏感性。 结果：我们鉴定出两种肝细胞癌特异性、基于5-甲基胞嘧啶的亚型（聚类1和聚类2）。与聚类2相比，聚类1的5-甲基胞嘧啶评分显著更高。基于5-甲基胞嘧啶的亚型能够准确预测肝细胞癌患者的经典分子亚型、免疫表型、预后及治疗机会。与聚类2（低5-甲基胞嘧啶评分）相比，聚类1（高5-甲基胞嘧啶评分）的特征为抗肿瘤免疫较低且预后较差。此外，聚类1（高5-甲基胞嘧啶评分）对癌症免疫治疗表现出低敏感性，但对放疗和仑伐替尼靶向治疗表现出高敏感性。 结论：这种新型的基于5-甲基胞嘧啶的亚型（根据5-甲基胞嘧啶评分）可能反映肝细胞癌患者的预后、肿瘤微环境及精准医学适用性。
【数据结构与技术规格】
文件数 1 个，合计 13.68 KB。Table4_Role of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in patients with hepatoc.XLSX：undefined，13.68 KB。数据集 DOI：10.3389/fgene.2022.984033.s008。
【主题与分类】
源站学科分类：Gene and Molecular Therapy、Gene Expression (incl. Microarray and other genome-wide approaches)、Genetics、Genetically Modified Animals、Livestock Cloning、Developmental Genetics (incl. Sex Determination)。主题标签：5 mC methylation、hepatocellular carcinoma (HCC)、immune escape、immunotherapy、biomarker。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://frontiersin.figshare.com/articles/dataset/Table4_Role_of_5-methylcytosine_in_determining_the_prognosis_tumor_microenvironment_and_applicability_of_precision_medicine_in_patients_with_hepatocellular_carcinoma_XLSX/21129523
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Luan, Mingyuan; Zhao, Min; Wang, Haiying; Xu, Rongjian; Cai, Jinzhen (2022). Table4_Role of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in patients with hepatocellular carcinoma.XLSX. Frontiers. Dataset
【使用注意】
· 源站最后修改于 2023-06-13，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Table4_Role of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in patients with hepatocellular carcinoma.XLSX
- DOI：10.3389/fgene.2022.984033.s008
- 发布日期：2022-09-16
- 文件数：1 个
- 文件总体积：13.68 KB
- 源站页面：https://frontiersin.figshare.com/articles/dataset/Table4_Role_of_5-methylcytosine_in_determining_the_prognosis_tumor_microenvironment_and_applicability_of_precision_medicine_in_patients_with_hepatocellular_carcinoma_XLSX/21129523
命令行下载
curl -L -o "Table4_Role of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in patients with hepatoc.XLSX" "https://ndownloader.figshare.com/files/37480450"
文件清单
Table4_Role of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in patients with hepatoc.XLSX（13.68 KB）
文件总体积 13.68 KB（源站 API 实测）。
数据说明
Background: 5-methylcytosine has a profound impact on the development and progression of hepatocellular carcinoma. The aim of this study was to investigate the usefulness of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in hepatocellular carcinoma.
Methods: We collected data of seven hepatocellular carcinoma cohorts (The Cancer Genome Atlas, International Cancer Genome Consortium, GSE14520, GSE6764, GSE9843, GSE63898, GSE76427). An unsupervised clustering method was used to identify novel subtypes of hepatocellular carcinoma based on the expression 5-methylcytosine gene signatures. The 5-methylcytosine score was determined using the least absolute shrinkage and selection operator method based on the differential expression of genes in the identified subtypes. Subsequently, we investigated the association between 5-methylcytosine-based clusters (according to the 5-methylcytosine score) and clinical outcomes, immunophenotypes, classical molecular subtypes, and therapeutic opportunities in hepatocellular carcinoma. Finally, we examined the sensitivity of patients with high 5-methylcytosine score to drugs.
Results: We identified two hepatocellular carcinoma-specific, 5-methylcytosine-based subtypes (clusters 1 and 2). Cluster 1 exhibited significantly higher 5-methylcytosine scores versus cluster 2. The 5-methylcytosine-based subtypes accurately predicted classical molecular subtypes, immunophenotypes, prognosis, and therapeutic opportunities for patients with hepatocellular carcinoma. Cluster 1 (high 5-methylcytosine score) was characterized by lower anticancer immunity and worse prognosis versus cluster 2 (low 5-methylcytosine score). Moreover, cluster 1 (high 5-methylcytosine score) exhibited low sensitivity to cancer immunotherapy, but high sensitivity to radiotherapy and targeted therapy with lenvatinib.
Conclusion: The novel 5-methylcytosine-based subtypes (according to the 5-methylcytosine score) may reflect the prognosis, tumor microenvironment, and applicability of precision medicine in patients with hepatocellular carcinoma.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.3389/fgene.2022.984033.s008（source: https://frontiersin.figshare.com/articles/dataset/Table4_Role_of_5-methylcytosine_in_determining_the_prognosis_tumor_microenvironment_and_applicability_of_precision_medicine_in_patients_with_hepatocellular_carcinoma_XLSX/21129523）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
